Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Geron Corp. -- Ignore unavailable to you. Want to Upgrade?

To: santhosh mohan who wrote (859)	1/23/1998 9:19:00 AM
From: Haolin Ni	Read Replies (2) \| Respond to of 3579

>if growth funds start shifting out of tech stocks due to the SE Asian problem, it may start going into the biotechs<. Thanks for the post. I do not agree you opinion about the GERN because market is showing oppsite way. Funds are getting into the tech companies and belive techs are bottom out but biotechs are still over valued. Funds may get into some biotech companies have profibility in near future not like GERN has nothing but a sientific paper. You should know that when GERN signed the agreement with Borhringer it has all the data in hand but get no money from Borhringer. I have shorted biotech companies for long time and GERN is one of the best shorts because it completely base on the hype and the blind belive of common investors. you could make several points as a long if it drop below $9. However, you must have good patience to wait it run up again since it has hurt a lot of people. You'd better to find some new story to play. Good luck!